Advertisement

Effects of Verapamil on Anthracycline-Induced Cardiomyopathy: Preliminary Results of a Prospective Multicenter Trial

  • J. Kraft
  • W. Grille
  • M. Appelt
  • D. K. Hossfeld
  • M. Eichelbaum
  • B. Koslowski
  • K. Quabeck
  • R. Kuse
  • T. Büchner
  • W. Hiddemann
  • M. C. Sauerland
  • F. Wendt
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 33)

Abstract

The use of anthracyclines and anthrachinones in antineoplastic treatment is limited by the possible induction of irreversible cardiomyopathy [1, 2, 6, 7, 9]. In 1976, Daniels et al. observed a protective effect of subcutaneously administered verapamil in white rabbits [4]. Mullerleile et al. reported a beneficial effect of low-dose oral verapamil in 22 patients with different tumors treated with doxorubicin [10]. The aim of this study was to determine whether verapamil can protect against anthracycline cardiomyopathy without altering the clinical efficiency of the antineoplastic regimen in patients with acute myeloid leukemia (AML) [8, 10–12].

Keywords

Acute Myeloid Leukemia Acute Myeloid Leukemia Patient Prospective Multicenter Trial Verapamil Group Antineoplastic Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Billingham ME, Mason JW, Bristow MR, Daniels JR (1978) Anthracycline cardiomyopathy monitoring by morphologic changes. Cancer Treat Rep 62: 865–872PubMedGoogle Scholar
  2. 2.
    Bristow MR, Billingham ME, Mason JW, Daniels JR (1978) Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 62: 873–879PubMedGoogle Scholar
  3. 3.
    Büchner T, Urbanitz D, Hiddemann W et al. (1986) Akute myeloische Leukämie (AML) des Erwachsenen. Weiterentwicklung der Therapie auf der Basis klinischer Phase-II und Phase-III-Studien. Onkologie 9: 83–91PubMedCrossRefGoogle Scholar
  4. 4.
    Daniels JR, Billingham ME, Gelbart A, Bristow MR (1976) Effect of verapamil and propanolol on adriamycin-induced cardiomyopathy in rabbits (Abstract). Circulation 53, 54 (Suppl II): 20Google Scholar
  5. 5.
    Freedman SB (1984) Pharmakokinetik von Calcium-Antagonisten. In: Althaus U (ed) Calcium-Antagonismus/Internat. Symposium on calcium antagonism. Universimed, Frankfurt, pp 30–49Google Scholar
  6. 6.
    Hofling B (1984) Die Anthracyclin-Kardiotoxizitat. Kehrer, FreiburgGoogle Scholar
  7. 7.
    Mason JW, Bristow MR, Billingham ME, Daniels JR (1978) Invasive and noninvasive methods assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep 62: 875Google Scholar
  8. 8.
    Klugmann S, Bartoldi Klugmann F, Decorti G, Gori D, Silvestri F, Camerini F (1981) Adriamycin experimental cardiomyopathy in Swiss mice. Different effects of two calcium antagonist drugs on ADM - cardiomyopathy. Pharmacol Res Commun 13: 769–776PubMedCrossRefGoogle Scholar
  9. 9.
    Mather F, Simon RM, Clark GM, von Hoff DD (1987) Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies. Cancer Treat Rep 71: 609–613PubMedGoogle Scholar
  10. 10.
    Müllerleile U, Garbrecht M, Hanrath P, Langenstein BA, Bieber K, Bleifeld W, Hossfeld DK (1984) Mögliche Prävention der Adriamycin induzierten Kardiomyopathie durch Verapamil. Klin Wochenschr 62: 1032–1037PubMedCrossRefGoogle Scholar
  11. 11.
    Polverino W, Basso A, Genovese A, Salvatore M, Pererone V, Muto P (1980) Verapamil and adriamycin cardiotoxicity. In: International symposium on calcium antagonism in cardiovascular therapy, Florence, October 2–4, 1980, pp 35–37Google Scholar
  12. 12.
    Rabkin SW, Godin DV (1985) Adriamycin cardiotoxicity and calcium entry blockers: the need for caution in the combination. Can J Cardiol 1 (5): 4–7Google Scholar
  13. 13.
    Villani V, Guindani A, Favalli L, Chiari C, Monti E, Piccinini F (1981) Role of cell calcium in the early and delayed cardiotoxicity of anthracyclines. Proc Am Assoc Cancer Res 22: 30Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • J. Kraft
    • 1
  • W. Grille
    • 2
  • M. Appelt
    • 2
  • D. K. Hossfeld
    • 3
  • M. Eichelbaum
    • 4
  • B. Koslowski
    • 1
  • K. Quabeck
    • 5
  • R. Kuse
    • 6
  • T. Büchner
    • 7
  • W. Hiddemann
    • 7
  • M. C. Sauerland
    • 8
  • F. Wendt
    • 1
  1. 1.Dept. of MedicineEvangelisches Krankenhaus Essen-WerdenGermany
  2. 2.Dept. of HematologyUniversity of KielGermany
  3. 3.Dept. of HematologyUniversity of HamburgGermany
  4. 4.Dr. Margarete Fischer Bosch Institute of Clinical PharmacologyStuttgartGermany
  5. 5.Dept. of Bone Marrow TransplantationUniversity of EssenGermany
  6. 6.Dept. of HematologyAllgemeines Krankenhaus St. GeorgHamburgGermany
  7. 7.Dept. of HematologyUniversity of MünsterGermany
  8. 8.Dept. of Medical BiostatisticsUniversity of MünsterGermany

Personalised recommendations